<p>与日内交易相比，长期持有公司的股票有显著的优势。买入并持有的方法更简单，不会让投资者受到短期且常常不理性的市场情绪的影响，限制了费用和税收，并且（尤其是在再投资股息的情况下）充分利用了复利的魔力。</p>
<p>尽管如此，即使在股息股票中，许多股票也不值得长期持有。让我们考虑一个值得长期持有的股息支付者：<strong>雅培</strong>（Abbott Laboratories）（ABT -2.47%）。这家医疗保健领导者具备成为永恒股票的特质。让我来解释一下。</p>
<h2>雅培的业务可能会弯曲，但不会崩溃</h2>
<p>大多数公司不会经营几十年。有时，甚至整个行业由于技术进步而变得过时。然而，在医疗保健行业，这种情况不太可能发生，雅培在该领域是领先者。由于多种原因，尤其是人口老龄化，医疗服务的需求预计将持续上升。医学在帮助我们活得更长、更健康方面的进步导致了对进一步发展的需求不断增长。</p>
<p>这对该行业来说是个好消息，但并不保证雅培的成功。为什么这家公司值得永远持有？以下是三个理由。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<p>首先，雅培实验室是其医疗设备专业领域中最成熟的公司之一，开发了数十种医生常用的产品。它与医生建立了良好的声誉和关系，这为其提供了显著的优势。</p>
<p>其次，雅培具有出色的创新能力——这是跟上行业需求变化的关键。该公司的某些产品在其细分市场中处于行业领先地位。其 MitraClip 是修复二尖瓣反流的顶级产品之一，开创了在该领域使用微创方法的先河。Amplatzer Occluder 设备系列帮助提高了心脏异常开口微创治疗的标准。</p>
<p>雅培的 FreeStyle Libre 系列，作为一系列连续血糖监测（CGM）系统，也在其领域中处于领先地位；它帮助开创了创新的 CGM 方法，相较于传统血糖仪显示出临床优势。FreeStyle Libre 已成为历史上销售额最高的医疗设备，突显了雅培的突破如何支持其产生强劲财务业绩的能力。</p>
<p>更重要的是，FreeStyle Libre 系列仍然拥有巨大的增长空间。正如雅培所指出的，CGM 市场的渗透率极低，全球只有约 1% 的糖尿病患者能够使用 CGM 技术。这就是为什么该公司的糖尿病护理部门近年来成为其主要增长动力之一，并且这一趋势预计将持续一段时间。</p>
<p>第三，雅培的整体业务是多元化的。虽然它以医疗设备的工作而闻名，但公司在品牌仿制药、诊断和营养等领域也有业务。这种多样性使其能够应对任何特定业务单元的挑战。值得指出的是，雅培的营养品牌包括著名的 Ensure 和 Similac。</p>
<p>因此，雅培销售的产品在经济条件下仍然保持高需求。它不断创新，在行业中拥有深厚的根基，并且有多个增长途径。股票可能会经历下跌，但即使在最糟糕的情况下也应该能够生存，并在之后继续表现良好。</p>
<h2>雅培拥有令人印象深刻的股息记录</h2>
<p>鉴于雅培业务的强劲，雅培拥有如此优秀的股息计划并不令人惊讶。几年前，它加入了股息之王的精英群体，这些公司已经连续提高股息至少 50 年；这家医疗设备巨头现在已经连续 53 年提高股息，并且没有结束的迹象。其现金支付比率约为 60.4%，这仍然是合理的，并为进一步增长股息提供了更多空间。</p>
<p>雅培实验室应该能够为长期投资者提供优异的回报，尤其是对于那些再投资股息的股东。</p>

雅培

<p>雅培（Abbott Laboratories，股票代码：ABT）被认为是长期投资的顶级分红股票，原因在于其在医疗保健领域的强大市场地位、创新产品和多元化的业务板块。该公司在医疗专业人士中享有良好的声誉和关系，这增强了其竞争优势。雅培的 FreeStyle Libre 是一款领先的连续血糖监测系统，体现了其创新和增长潜力。雅培连续 53 年提高分红，且合理的派息比率为 60.4%，因此在长期回报方面表现出色，尤其适合那些选择再投资分红的投资者</p>

<p>There are significant advantages to holding shares of companies for a long time as opposed to, say, day trading. The buy-and-hold approach is simpler, doesn't leave investors at the mercy of short-term and often irrational market sentiment, limits fees and taxes, and (especially when dividends are reinvested) puts the magic of compounding to work.</p>
<div class="lb-trans"><p>与日内交易相比，长期持有公司的股票有显著的优势。买入并持有的方法更简单，不会让投资者受到短期且常常不理性的市场情绪的影响，限制了费用和税收，并且（尤其是在再投资股息的情况下）充分利用了复利的魔力。</p>
</div><p>That being said, even among dividend stocks, many aren't worth sticking with for the long term. Let's consider one dividend payer that is: <strong>Abbott Laboratories</strong>(ABT -2.47%). This healthcare leader has the qualities of a forever stock. Let me explain.</p>
<div class="lb-trans"><p>尽管如此，即使在股息股票中，许多股票也不值得长期持有。让我们考虑一个值得长期持有的股息支付者：<strong>雅培</strong>（Abbott Laboratories）（ABT -2.47%）。这家医疗保健领导者具备成为永恒股票的特质。让我来解释一下。</p>
</div><h2>Abbott's business might bend, but it won't break</h2>
<div class="lb-trans"><h2>雅培的业务可能会弯曲，但不会崩溃</h2>
</div><p>Most companies don't stay in business for decades. Sometimes, even entire industries become obsolete due to technological advances. The latter is unlikely to happen in the healthcare sector, where Abbott Laboratories is a leading player. The demand for medical services should remain on the rise for a slew of reasons, particularly an aging population. Medicine's progress in helping us live longer and healthier lives has led to a growing need for further advancements.</p>
<div class="lb-trans"><p>大多数公司不会经营几十年。有时，甚至整个行业由于技术进步而变得过时。然而，在医疗保健行业，这种情况不太可能发生，雅培在该领域是领先者。由于多种原因，尤其是人口老龄化，医疗服务的需求预计将持续上升。医学在帮助我们活得更长、更健康方面的进步导致了对进一步发展的需求不断增长。</p>
</div><p>That's excellent news for the sector, but it doesn't guarantee Abbott Laboratories' success. Why is the company worth sticking with forever? Here are three reasons.</p>
<div class="lb-trans"><p>这对该行业来说是个好消息，但并不保证雅培的成功。为什么这家公司值得永远持有？以下是三个理由。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84MzczMzgvc3VyZ2VvbnMtaW4tYW4tb3BlcmF0aW5nLXJvb20uanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F837338%2Fsurgeons-in-an-operating-room.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>First, Abbott Labs is one of the most well-established companies in its medical device specialty, and has developed dozens of products that physicians routinely use. It has built a strong reputation and relationships with doctors, which grant it a significant advantage.</p>
<div class="lb-trans"><p>首先，雅培实验室是其医疗设备专业领域中最成熟的公司之一，开发了数十种医生常用的产品。它与医生建立了良好的声誉和关系，这为其提供了显著的优势。</p>
</div><p>Second, Abbott has an excellent innovative streak -- that's the key to keeping pace with the changing demands of the sector. Some of the company's products are among the industry leaders in their niches. Its MitraClip is one of the top products used to fix mitral valve regurgitation, having pioneered the use of minimally invasive approaches in this area. The family of Amplatzer Occluder devices helped raise the standard for the minimally invasive treatment of abnormal openings in the heart.</p>
<div class="lb-trans"><p>其次，雅培具有出色的创新能力——这是跟上行业需求变化的关键。该公司的某些产品在其细分市场中处于行业领先地位。其 MitraClip 是修复二尖瓣反流的顶级产品之一，开创了在该领域使用微创方法的先河。Amplatzer Occluder 设备系列帮助提高了心脏异常开口微创治疗的标准。</p>
</div><p>Abbott's FreeStyle Libre franchise, a family of continuous glucose monitoring (CGM) systems, is also among the leaders in its area; it helped pioneer the innovative CGM approach, which shows clinical benefits over traditional blood glucose meters. The FreeStyle Libre has become the most successful medical device in history in terms of dollar sales, highlighting how Abbott's breakthroughs support its ability to generate strong financial results.</p>
<div class="lb-trans"><p>雅培的 FreeStyle Libre 系列，作为一系列连续血糖监测（CGM）系统，也在其领域中处于领先地位；它帮助开创了创新的 CGM 方法，相较于传统血糖仪显示出临床优势。FreeStyle Libre 已成为历史上销售额最高的医疗设备，突显了雅培的突破如何支持其产生强劲财务业绩的能力。</p>
</div><p>What's more, the FreeStyle Libre franchise still has a massive growth runway ahead. As Abbott has pointed out, the CGM market is severely underpenetrated, as only about 1% of diabetes patients worldwide have access to CGM technology. That's why the company's diabetes care segment has been one of its major growth drivers in recent years, and this trend should continue for a while.</p>
<div class="lb-trans"><p>更重要的是，FreeStyle Libre 系列仍然拥有巨大的增长空间。正如雅培所指出的，CGM 市场的渗透率极低，全球只有约 1% 的糖尿病患者能够使用 CGM 技术。这就是为什么该公司的糖尿病护理部门近年来成为其主要增长动力之一，并且这一趋势预计将持续一段时间。</p>
</div><p>Third, Abbott's overall business is diversified. While it's best known for its work in medical devices, the company also has segments in branded generic pharmaceuticals, diagnostics, and nutrition. This diversity can allow it to navigate challenges in any particular business unit. It's also worth pointing out that Abbott's nutrition brands include famous ones like Ensure and Similac.</p>
<div class="lb-trans"><p>第三，雅培的整体业务是多元化的。虽然它以医疗设备的工作而闻名，但公司在品牌仿制药、诊断和营养等领域也有业务。这种多样性使其能够应对任何特定业务单元的挑战。值得指出的是，雅培的营养品牌包括著名的 Ensure 和 Similac。</p>
</div><p>So, Abbott markets products that remain in high demand regardless of economic conditions. It constantly innovates, has deep footprints in the industry, and has several growth avenues. The stock might experience a downturn, but should survive even the worst and continue performing well long afterward.</p>
<div class="lb-trans"><p>因此，雅培销售的产品在经济条件下仍然保持高需求。它不断创新，在行业中拥有深厚的根基，并且有多个增长途径。股票可能会经历下跌，但即使在最糟糕的情况下也应该能够生存，并在之后继续表现良好。</p>
</div><h2>Abbott boasts an impressive dividend track record</h2>
<div class="lb-trans"><h2>雅培拥有令人印象深刻的股息记录</h2>
</div><p>Given the strength of Abbott's business, it's not surprising that it has such an excellent dividend program. It joined the elite group of Dividend Kings, companies that have raised their payouts for at least 50 consecutive years, just a few years ago; the medical device giant has now had 53 straight years of dividend hikes, and there's no end in sight. Its cash payout ratio is about 60.4%, which is still reasonable and grants plenty more room to grow the dividend further.</p>
<div class="lb-trans"><p>鉴于雅培业务的强劲，雅培拥有如此优秀的股息计划并不令人惊讶。几年前，它加入了股息之王的精英群体，这些公司已经连续提高股息至少 50 年；这家医疗设备巨头现在已经连续 53 年提高股息，并且没有结束的迹象。其现金支付比率约为 60.4%，这仍然是合理的，并为进一步增长股息提供了更多空间。</p>
</div><p>Abbott Laboratories should provide excellent long-term returns, especially for shareholders who reinvest the dividend.</p>
<div class="lb-trans"><p>雅培实验室应该能够为长期投资者提供优异的回报，尤其是对于那些再投资股息的股东。</p>
</div>

一只值得长期买入并持有的无脑股息股票